Adeno-Associated Virus (AAV) CDMO Market Size
| Study Period | 2021 - 2029 |
| Market Size (2024) | USD 0.57 Billion |
| Market Size (2029) | USD 1.40 Billion |
| CAGR (2024 - 2029) | 20.86 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Adeno-Associated Virus (AAV) CDMO Market Analysis
The Adeno-Associated Virus CDMO Market size is estimated at USD 0.57 billion in 2024, and is expected to reach USD 1.40 billion by 2029, growing at a CAGR of 20.86% during the forecast period (2024-2029).
The key factors driving the growth of the adeno-associated virus CDMO market include the increasing use of gene therapy, advancements in AAV vectors, and rising outsourcing of AAV vector manufacturing.
Companies operating in the AAV development field are developing new technologies and engaging in strategic activities that benefit the market. For instance, in November 2022, Thermo Fisher Scientific introduced the Gibco CTS adeno-associated virus (AAV) MAX Helper Free production system, which it claims can save time and reduce costs by 50%. The CTS AAV-MAX system includes several components: mammalian cells, a cell culture medium, a transfection kit, and a buffer.
In February 2022, Mirus Bio launched Transit-VirusGEN SELECT Transfection Kits for large-scale viral vector production for cell and gene therapy applications. The kits support pre-clinical and process development activities and consist of the TransIT-VirusGEN Transfection Reagent, a complex formation solution, and an enhancer. Hence, the introduction of AAV technologies is expected to increase its demand, and production is likely to boost the demand for CDMO services over the forecast period.
Furthermore, growing research identifying the importance of gene therapy in treating life-threatening diseases is propelling market growth. For instance, the study published in the Radiology and Oncology Journal in February 2022 claimed that the use of adeno-associated viral vectors to treat cancer had the potential to change the area of oncology. Virus vectors, in particular, provide a unique mix of effective gene delivery and immune system engagement for anti-tumour responses. Such studies are expected to increase the adoption of AAV contract manufacturing in designing cancer therapies, driving market growth.
However, production capacity challenges and regulatory issues are expected to hinder market growth in the long run.
Adeno-Associated Virus (AAV) CDMO Market Trends
Cell and Gene Therapy Development is Expected to Witness Rapid Growth Over the Forecast Period
Cell and gene therapy development is one of the most rapidly evolving segments. Several developments are occurring in the cell and gene therapy space that are driving segmental growth. For instance, in June 2023, Laurus Labs Ltd, one of the pharma companies in India, inked a memorandum of agreement (MoA) with IIT Kanpur (IITK) for in-licensing novel gene therapy assets using AAV vectors and bringing them to market.
Similarly, in December 2022, Merck partnered with Synplogen, a Kobe University spin-off, to enhance gene therapy development in Japan. This collaboration combined Merck's CTDMO expertise with Synplogen's capabilities, facilitating streamlined processes for gene therapy development, manufacturing, and testing.
In August 2022, Polyplus unveiled its groundbreaking Transgene Plasmid Engineering Services tailored specifically for viral vector production. The expansion of Polyplus' plasmid services provided a comprehensive range of options for next-generation viral vector and gene therapy manufacturing. These services can be utilized independently or in conjunction with the industry-standard PEIpro and FectoVIR-AAV reagents and kits. In May 2022, AGC Biologics expanded its Longmont, Colorado facility, adding viral vector suspension technology and capacity to support the development and manufacturing of gene therapies. These new capabilities, which were launched online in the third quarter of 2022, enhanced the site's existing viral vector and cell therapy services.
Consequently, due to factors such as the burgeoning involvement of companies in cell and gene therapy and robust collaborations among them, the cell and gene therapy segment is poised for significant growth in the future.
North America is Expected to Dominate the Market During the Forecast Period
North America is expected to dominate the market due to factors such as the well-established pharmaceutical and biotechnology industry and the rising focus on contract manufacturing across the region.
The companies are investing in research and development of gene therapy. For instance, in October 2022, Astellas invested USD 50 million in Taysha Gene Therapies Inc. in order to gain access to two of its AAV gene therapy initiatives for Rett syndrome and giant axonal neuropathy (GAN). Similarly, the National Cancer Institute (NIC), based on data updated in March 2022, was given USD 6.9 billion by the Consolidated Appropriations Act 2022. This was a net increase of USD 353 million over FY 2021. The FY 2022 allocation included USD 194 million in funding for the Cancer Moonshot and USD 50 million for the Childhood Cancer Data Initiative. Thus, increasing investments in enabling a precision medicine approach across the country are expected to drive the market during the forecast period.
Companies operating in the area are investing heavily in the research and development of advanced and effective therapeutics for cancer treatment and launching new products, which is expected to further boost the growth of the cancer segment in the market studied.
In November 2022, the US Food and Drug Administration approved Hemgenix, an adeno-associated virus vector-based gene therapy for treating adults with Hemophilia B or life-threatening historical hemorrhage or who have repeated, serious, severe spontaneous bleeding episodes.
The North American market is experiencing growth as a result of increasing investments by companies and the presence of a well-established pharmaceutical industry in the region.
Adeno-Associated Virus (AAV) CDMO Industry Overview
The market for AAV CDMO is moderately competitive, with several companies operating globally. The companies are mainly focusing on strategic activities such as collaboration, mergers, acquisitions, and partnerships to sustain themselves in the market. Some of the key players operating in the market include Thermo Fischer Scientific Inc., Creative Biogene, Catalent Inc., Charles River Laboratories International Inc., and Danaher (Aldevron).
Adeno-Associated Virus (AAV) CDMO Market Leaders
-
Thermo Fischer Scientific Inc.
-
Creative Biogene
-
Catalent Inc.
-
Charles River Laboratories International Inc.
-
Aldevron
*Disclaimer: Major Players sorted in no particular order
Adeno-Associated Virus (AAV) CDMO Market News
- March 2024: Charles River Laboratories International Inc. and Navega Therapeutics Inc. entered into an agreement for the production of AAV9. Under Charles River's Cell and Gene Therapy Accelerator Program (CAP), Navega will utilize the company's CDMO capabilities and advisory services for the production of NT-Z001, an AAV-based gene therapy.
- March 2023: Charles River Laboratories International Inc. announced the launch of its off-the-shelf pHelper offering. This is designed to secure supply and streamline adeno-associated virus (AAV)-based gene therapy programs from early discovery through commercial manufacturing.
Adeno-Associated Virus (AAV) CDMO Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Adeno-Associated Virus (AAV) Pipeline: Promising Gene Therapy and Vaccine Prospects
- 4.2.2 Advancements in Adeno-Associated Viral Vector Manufacturing
- 4.2.3 Rising Outsourcing of AAV Vector Manufacturing and Intense Competition and Diverse Strategies in the Market
-
4.3 Market Restraints
- 4.3.1 Regulatory, Scientific, and Ethical Challenges Associated with Gene Therapy and Viral Vectors
- 4.3.2 Manufacturing Challenges in Producing AAV Viral Vectors
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size - Value in USD)
-
5.1 By Workflow
- 5.1.1 Upstream Processing
- 5.1.2 Downstream Processing
-
5.2 By Culture Type
- 5.2.1 Adherent Culture
- 5.2.2 Suspension Culture
-
5.3 By Application
- 5.3.1 Cell & Gene Therapy Development
- 5.3.2 Vaccine Development
- 5.3.3 Biopharmaceutical & Pharmaceutical Discovery
- 5.3.4 Biomedical Research
-
5.4 By End User
- 5.4.1 Pharmaceutical & Biopharmaceutical Companies
- 5.4.2 Academic & Research Institutes
-
5.5 Geography
- 5.5.1 North America
- 5.5.1.1 United States
- 5.5.1.2 Canada
- 5.5.1.3 Mexico
- 5.5.2 Europe
- 5.5.2.1 Germany
- 5.5.2.2 United Kingdom
- 5.5.2.3 France
- 5.5.2.4 Italy
- 5.5.2.5 Spain
- 5.5.2.6 Rest of Europe
- 5.5.3 Asia-Pacific
- 5.5.3.1 China
- 5.5.3.2 Japan
- 5.5.3.3 India
- 5.5.3.4 Australia
- 5.5.3.5 South Korea
- 5.5.3.6 Rest of Asia-Pacific
- 5.5.4 Middle East and Africa
- 5.5.4.1 GCC
- 5.5.4.2 South Africa
- 5.5.4.3 Rest of Middle East and Africa
- 5.5.5 South America
- 5.5.5.1 Brazil
- 5.5.5.2 Argentina
- 5.5.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Aldevron LLC
- 6.1.2 Charles River Laboratories Inc.
- 6.1.3 Forge Biologics Holdings, LLC (a member of Ajinomoto Bio-Pharma Services)
- 6.1.4 Creative Biogene
- 6.1.5 Genezen
- 6.1.6 Viralgen Vector Core S.L.
- 6.1.7 Catalent Inc.
- 6.1.8 Merck KGaA
- 6.1.9 ViroCell Biologics Ltd
- 6.1.10 Biovian Oy
- 6.1.11 Thermo Fisher Scientific Inc.
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityAdeno-Associated Virus (AAV) CDMO Industry Segmentation
As per the scope of the report, AAV is a protein shell surrounding and protecting a small, single-stranded DNA genome. AAV CDMO refers to the contract manufacturing organizations that are involved in the development of AAV.
The AAV CDMO market is segmented by workflow, culture type, application, end user, and geography. By workflow, the market is segmented into upstream processing and downstream processing. By culture type, the market is segmented into adherent culture and suspension culture. By application, the market is segmented into cell & gene therapy development, vaccine development, biopharmaceutical & pharmaceutical discovery, and biomedical research. By end user, the market is segmented into pharmaceutical & biopharmaceutical companies and academic & research institutes. By geography, the market is segmented into North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD) for all the above segments.
| By Workflow | Upstream Processing | |
| Downstream Processing | ||
| By Culture Type | Adherent Culture | |
| Suspension Culture | ||
| By Application | Cell & Gene Therapy Development | |
| Vaccine Development | ||
| Biopharmaceutical & Pharmaceutical Discovery | ||
| Biomedical Research | ||
| By End User | Pharmaceutical & Biopharmaceutical Companies | |
| Academic & Research Institutes | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle East and Africa | GCC |
| South Africa | ||
| Rest of Middle East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Adeno-Associated Virus (AAV) CDMO Market Research FAQs
How big is the Adeno-Associated Virus CDMO Market?
The Adeno-Associated Virus CDMO Market size is expected to reach USD 0.57 billion in 2024 and grow at a CAGR of 20.86% to reach USD 1.40 billion by 2029.
What is the current Adeno-Associated Virus CDMO Market size?
In 2024, the Adeno-Associated Virus CDMO Market size is expected to reach USD 0.57 billion.
Who are the key players in Adeno-Associated Virus CDMO Market?
Thermo Fischer Scientific Inc., Creative Biogene, Catalent Inc., Charles River Laboratories International Inc. and Aldevron are the major companies operating in the Adeno-Associated Virus CDMO Market.
Which is the fastest growing region in Adeno-Associated Virus CDMO Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Adeno-Associated Virus CDMO Market?
In 2024, the North America accounts for the largest market share in Adeno-Associated Virus CDMO Market.
What years does this Adeno-Associated Virus CDMO Market cover, and what was the market size in 2023?
In 2023, the Adeno-Associated Virus CDMO Market size was estimated at USD 0.45 billion. The report covers the Adeno-Associated Virus CDMO Market historical market size for years: 2021, 2022 and 2023. The report also forecasts the Adeno-Associated Virus CDMO Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Adeno-Associated Virus (AAV) CDMO Industry Report
Statistics for the 2024 Adeno-Associated Virus (AAV) CDMO market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Adeno-Associated Virus (AAV) CDMO analysis includes a market forecast outlook for 2024 to (2024to2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
